Summary
a2 Milk Company's global revenue for H1 FY2025 (to 31 December 2024) was NZD 893.8 million (approx. RMB 3.72 billion), up 10.1% year-on-year. Revenue from China and other Asian markets reached NZD 614.2 million (approx.
RMB 2.56 billion), accounting for 68.7% of global revenue, an increase of 11.8%. The market share of Chinese-label a2 Platinum infant formula hit a record high of 5.3%, with total infant formula sales of NZD 604.7 million, up 7.2%, achieving double-digit growth in China and maintaining a top-five brand position. The company announced its first dividend policy, distributing 67% of net profit.
CEO David Bortolussi raised FY2025 revenue guidance to low-to-mid single-digit growth. Future plans include expanding the family nutrition strategy, registering more Chinese-label infant formula products, establishing an R&D centre in Shanghai, and exploring local production partnerships.
Commentary
a2 Milk Company's financial results offer multiple insights for New Zealand small and medium-sized enterprises (SMEs). On the positive side, a2's counter-trend growth in China demonstrates strong demand for premium New Zealand dairy, especially in infant formula, where Chinese-label products achieved record market share. This suggests SMEs could focus on Chinese consumers' emphasis on brand traceability and quality, considering entry via cross-border e-commerce or local channel partnerships.
Meanwhile, a2's plan to build an R&D centre in Shanghai and explore local production may signal future manufacturing in China, posing a potential challenge for SME suppliers reliant on New Zealand origin – they need to strengthen differentiation, such as organic or grass-fed attributes. On the other hand, a2's first dividend and raised guidance indicate robust cash flow, but China's infant formula market faces intensifying competition and higher registration thresholds under new regulations. SMEs should cautiously assess their resources and avoid blind following.
Conclusion: a2's performance and initiatives show China still offers a window of opportunity, but the rewards tend to favour companies with technological barriers and brand equity; smaller firms should target niche segments.
Keywords: a2 Milk Company, infant formula, China market, revenue growth, market share, a2 Platinum, Chinese label, R&D centre, localisation, dividend
Source: None
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.
